As part of their ongoing collaboration in the development and commercialization of fusion inhibitors for the treatment of HIV/AIDS, Roche and Trimeris, Inc. today announced the selection of two next-generation fusion inhibitor peptides for co-development and progression into further pre- clinical studies. The peptides, TR-291144 and TR-290999, first synthesized at Trimeris, are distinct compounds derived from HR2 sequences of HIV. In connection with this event, Trimeris will receive a payment from Roche.

Biotech Intelligence (http://www.biotech-intelligence.com/html/html/da16f8fcadd3575accd4ed0c3b9afd21.html)